Complexes of Ibuprofen Thiazolidin-4-One Derivatives with -Cyclodextrin: Characterization and In Vivo Release Profile and Biological Evaluation

Generally, NSAIDs are weakly soluble in water and contain both hydrophilic and hydrophobic groups. One of the most widely used NSAIDs is ibuprofen, which has a poor solubility and high permeability profile. By creating dynamic, non-covalent, water-soluble inclusion complexes, cyclodextrins (CDs) can increase the dissolution rate of low aqueous solubility drugs, operating as a drug delivery vehicle, additionally contributing significantly to the chemical stability of pharmaceuticals and to reducing drug-related irritability. In order to improve the pharmacological and pharmacokinetics profile of ibuprofen, new thiazolidin-4-one derivatives of ibuprofen (4b, 4g, 4k, 4m) were complexed with beta-CD, using co-precipitation and freeze-drying. The new beta-CD complexes (beta-CD-4b, beta-CD-4g, beta-CD-4k, beta-CD-4m) were characterized using scanning electronic microscopy (SEM), differential scanning calorimetry (DSC), X-ray diffraction and a phase solubility test. Using the AutoDock-VINA algorithm included in YASARA-structure software, we investigated the binding conformation of ibuprofen derivatives to beta-CD and measured the binding energies. We also performed an in vivo biological evaluation of the ibuprofen derivatives and corresponding beta-CD complexes, using analgesic/anti-inflammatory assays, as well as a release profile. The results support the theory that beta-CD complexes (beta-CD-4b, beta-CD-4g, beta-CD-4k, beta-CD-4m) have a similar effect to ibuprofen derivatives (4b, 4g, 4k, 4m). Moreover, the beta-CD complexes demonstrated a delayed release profile, which provides valuable insights into the drug-delivery area, focused on ibuprofen derivatives.